MOLECULAR INFORMATION
Molecular information
- Type
- Dual GLP-1 / glucagon receptor agonist · investigational, development paused
Cotadutide is AstraZeneca’s investigational dual GLP-1 / glucagon receptor agonist. Phase 2 demonstrated weight loss and improvements in metabolic markers, but Phase 3 development was deprioritised in favour of competing internal programmes.
Status
- Phase 2 completed
- Phase 3 development paused by sponsor (commercial decision)
- Not authorised; no active clinical trials known
Why we grade it C
Real Phase 2 human data with a plausible signal, but the programme was discontinued before pivotal trials. Promotion blocked by absent Phase 3 read-outs. Listed because the data persists in the literature and grey-market chemists occasionally resurface the molecule.